Clinical Trial Update: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating XL092 as a single-agent and combination therapy for solid tumors, including renal cell carcinoma, hormone receptor-positive breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Hormone Receptor-positive Breast Cancer
• Renal Cell Carcinoma

Drugs mentioned

• XL092

Snippet

Sponsor: Exelixis | Conditions: Neoplasm Malignant, Renal Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING